Abstract
Oncology advanced practitioners treating relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (NHLs) are practicing in a rapidly evolving landscape with options expanding to include BTK inhibitors, bispecific antibodies, and CAR T-cell therapies. At JADPRO Live 2025, speakers discussed sequencing and how mechanistic, safety, financial, logistical, and quality-of-life factors shape decision-making.
